The association remained significant after matching for key risk factors, such as age, race, ethnicity, BMI, breast density, and diabetes status, suggesting the findings were not solely due to differences between groups
S., Schell, T
Altered mitochondrial fusion drives defensive glutathione synthesis in cells able to switch to glycolytic ATP production
Tirzepatide (Mounjaro, Zepbound, compounded) Tirzepatide is a dual GIP/GLP-1 receptor agonist, which means its mechanism differs slightly from pure GLP-1 medications
Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M et al